Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

A number of other brokerages have also weighed in on HOTH. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Tuesday, January 7th. Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price objective on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Stock Up 8.1 %

Shares of NASDAQ:HOTH opened at $1.47 on Thursday. The company has a market capitalization of $10.14 million, a P/E ratio of -1.11 and a beta of 0.75. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $0.91.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, sell-side analysts anticipate that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.